How EU Medicine Pricing and Reimbursement Really Works: An Interactive Explainer

Why can a drug be approved across the entire European Union but still be unavailable to patients in certain member states? The answer lies in the complex system of pharmaceutical pricing, reimbursement, intellectual property protection, supply chain fragility, and access program design that governs how medicines move from laboratory to patient. This interactive group chat walks you through four stories featuring the key stakeholders who shape medicine access in Europe — including the Trump administration’s Most Favored Nation pricing policy, which is now reshaping the incentives of European price negotiations in real time.

Choose a story and press play

Use the menu on the left to switch between the four stories. Use the playback controls to start, pause, skip forward, or step back. Adjust the speed to read at your own pace. The abbreviation reference on the right explains technical terms as they appear. Each story has five acts.

The core problem

In the EU, marketing authorisation for a new medicine is handled centrally by the European Medicines Agency (EMA). Once approved, a drug can legally be sold in all 27 member states. However, whether public health insurance will pay for that drug is decided at the national level — each country individually runs a Health Technology Assessment (HTA) and negotiates a price with the manufacturer. This creates a strategic game: companies launch first in high-price countries like Germany and Switzerland to set high reference prices, then delay or skip smaller and lower-income markets entirely. Almost all EU countries use External Price Referencing (EPR), benchmarking their own prices against others, which makes every national price negotiation a global pricing decision in disguise.

A new external pressure has entered this system: the US Trump administration’s Most Favored Nation (MFN) policy references the lowest prices among 19 OECD countries — including most EU member states — as a ceiling for what Medicare pays. This creates a perverse incentive: aggressive European price negotiation now risks propagating back into the far larger US market. Germany has already introduced confidential pricing options specifically to keep its negotiated prices invisible to the MFN benchmark. The downstream consequences for patient access in lower-income EU member states are still unfolding.

Even when pricing works as intended, patients still face structural barriers: supply chains built for cost efficiency rather than resilience, medicines that vanish from pharmacy shelves, and a parallel universe of pre-approval access programs that follow commercial logic while being described as charity. The four stories below examine each of these failure modes in turn.

What you will learn

Story 1 — The Cancer Drug follows a new oncology drug through the full EU pricing labyrinth: EMA approval, the launch-country sequencing strategy, confidential discount deals, patent thickets blocking generics, and the limits of what EU legislation can actually force.

Story 2 — The Rare Disease explores orphan drugs for small patient populations, where standard cost-effectiveness thresholds break down entirely, HTA bodies face impossible choices, and patients in Poland wait while patients in Italy are already being treated — with the same drug, for the same disease.

Story 3 — The Shortage examines why antibiotics disappeared from pharmacy shelves across Europe in 2022–2023: three decades of cost-optimised offshoring, price floors that make manufacturing unviable, 27 fragmented notification systems, and a Critical Medicines Act that monitors better than it enforces.

Story 4 — Compassionate Use exposes the shadow system of pre-approval access: pharmaceutical companies providing free drugs to dying patients before authorisation — while collecting real-world data for their reimbursement dossier, building physician relationships, and strategically timing programs to create political pressure at HTA decision day. And deciding which countries are “strategic” enough to be included.

All four stories feature the voices of major stakeholders: the European Commission, pharmaceutical companies, national health authorities, the pharma industry lobby (EFPIA), generic and biosimilar manufacturers, hospital pharmacists, doctors, health insurers, the WHO, patients, and Volt Europa — as well as the US administration as an external actor reshaping the game from outside.